Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients With Symp-tomatic Visceral Metastases or High Tumor Burden

NCT04681768 is registered in ClinicalTrials.gov with Technical University of Munich as lead sponsor.

NCT NCT04681768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04681768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients With Symp-tomatic Visceral Metastases or High Tumor Burden
Lead sponsor
Technical University of Munich
Phase
Observational
Overall status
Completed
Start date
December 22, 2020
Completion date
April 1, 2025
Enrollment
95 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer/ metastatic breast cancer